X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Merck gains Caraway's pipeline of novel, small-molecule therapeutics for the treatment of genetically defined neurodegenerative and rare diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $610.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 21, 2023
Details:
TRPML1 is a non-selective cation channel that contributes to the regulation of lysosomal ionic contents and mediates communication with the rest of the cell.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
TRPML1 normally functions to regulate and maintain the ionic composition in the lysosome, and mutations in TRPML1 lead to Mucolipidosis Type IV, which is typified by lysosomal dysfunction and toxic accumulation of proteins and lipids that have not been efficiently recycled.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
TRPML1, a member of the transient receptor potential ion channel superfamily, targeting the lysosomal cation channel for the treatment of GBA-PD and other neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The Company will use the grant funding to further evaluate these effects and characterize potential biomarkers which may be used in future clinical trials of TRPML1 activators.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson’s Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2022
Details:
Collaboration to focus on development of TMEM175 modulators in Parkinson’s disease and other neurodegenerative disorders. Leverages Caraway’s unique drug discovery platform and expertise in cellular clearance.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $267.0 million Upfront Cash: $17.0 million
Deal Type: Collaboration June 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
